{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T19:45:19Z","timestamp":1791402319812,"version":"4.3.3"},"reference-count":62,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2017,6,1]],"date-time":"2017-06-01T00:00:00Z","timestamp":1496275200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,6,1]],"date-time":"2017-06-01T00:00:00Z","timestamp":1496275200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jiac-j.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Infection and Chemotherapy"],"published-print":{"date-parts":[[2017,6]]},"DOI":"10.1016\/j.jiac.2017.02.011","type":"journal-article","created":{"date-parts":[[2017,3,22]],"date-time":"2017-03-22T01:48:31Z","timestamp":1490147311000},"page":"360-367","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"title":["Evaluation of the implementation rate of primary antifungal prophylaxis and the prognosis of invasive fungal disease in acute leukemia patients in China"],"prefix":"10.1016","volume":"23","author":[{"given":"Xiao-han","family":"Xu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin-xin","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tie-nan","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua-cong","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miao","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bing","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun-ling","family":"Zhuang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dao-bin","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming-hui","family":"Duan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jiac.2017.02.011_bib1","doi-asserted-by":"crossref","first-page":"e0128410","DOI":"10.1371\/journal.pone.0128410","article-title":"High incidences of invasive fungal infections in acute myeloid leukemia patients receiving induction chemotherapy without systemic antifungal prophylaxis: a prospective observational study in Taiwan","volume":"10","author":"Tang","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.jiac.2017.02.011_bib2","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.diagmicrobio.2012.10.001","article-title":"Epidemiology, outcomes, and risk factors of invasive fungal infections in adult patients with acute myelogenous leukemia after induction chemotherapy","volume":"75","author":"Neofytos","year":"2013","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.jiac.2017.02.011_bib3","first-page":"1","article-title":"Epidemiology of invasive fungal infections during induction therapy in adults with acute lymphoblastic leukemia: a GRAALL-2005 study","author":"Mariette","year":"2016","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.jiac.2017.02.011_bib4","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.3109\/10428194.2012.740561","article-title":"Incidence and outcomes of invasive fungal disease in adult patients with acute lymphoblastic leukemia treated with hyperfractionated cyclophosphamide, vincristine, doxorubicin and dexamethasone: implications for prophylaxis","volume":"54","author":"Henden","year":"2013","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.jiac.2017.02.011_bib5","doi-asserted-by":"crossref","first-page":"337","DOI":"10.3324\/haematol.2010.030825","article-title":"Impact of invasive fungal disease on the chemotherapy schedule and event-free survival in acute leukemia patients who survived fungal disease: a case-control study","volume":"96","author":"Even","year":"2011","journal-title":"Haematologica"},{"key":"10.1016\/j.jiac.2017.02.011_bib6","first-page":"1068","article-title":"The epidemiology of fungal infections in patients with hematologic malignancies: the SEIFEM-2004 study","volume":"91","author":"Pagano","year":"2006","journal-title":"Haematologica"},{"key":"10.1016\/j.jiac.2017.02.011_bib7","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1007\/s13277-014-2649-7","article-title":"Invasive fungal infection in patients receiving chemotherapy for hematological malignancy: a multicenter, prospective, observational study in China","volume":"36","author":"Sun","year":"2015","journal-title":"Tumour Biol"},{"key":"10.1016\/j.jiac.2017.02.011_bib8","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.3109\/10428194.2011.636812","article-title":"Infectious complications in adult acute myeloid leukemia: analysis of the Acute Leukemia French Association-9802 prospective multicenter clinical trial","volume":"53","author":"Cannas","year":"2012","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.jiac.2017.02.011_bib9","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1046\/j.1365-2141.2003.04728.x","article-title":"Fludarabine, cytosine arabinoside, granulocyte-colony stimulating factor with or without idarubicin in the treatment of high risk acute leukaemia or myelodysplastic syndromes","volume":"124","author":"Virchis","year":"2004","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jiac.2017.02.011_bib10","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1038\/bmt.2010.175","article-title":"European guidelines for antifungal management in leukemia and hematopoietic stem cell transplant recipients: summary of the ECIL 3\u20132009 update","volume":"46","author":"Maertens","year":"2011","journal-title":"Bone Marrow Transpl"},{"key":"10.1016\/j.jiac.2017.02.011_bib11","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1007\/s00277-014-2108-y","article-title":"Primary prophylaxis of invasive fungal infections in patients with haematologic malignancies. 2014 update of the recommendations of the Infectious Diseases Working Party of the German Society for Haematology and Oncology","volume":"93","author":"Tacke","year":"2014","journal-title":"Ann Hematol"},{"key":"10.1016\/j.jiac.2017.02.011_bib12","doi-asserted-by":"crossref","first-page":"e56","DOI":"10.1093\/cid\/cir073","article-title":"Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America","volume":"52","author":"Freifeld","year":"2011","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jiac.2017.02.011_bib13","doi-asserted-by":"crossref","first-page":"e0140930","DOI":"10.1371\/journal.pone.0140930","article-title":"Meta-analysis and cost comparison of empirical versus pre-emptive antifungal strategies in hematologic malignancy patients with high-risk febrile neutropenia","volume":"10","author":"Fung","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.jiac.2017.02.011_bib14","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1097\/00001432-200208000-00003","article-title":"Prophylaxis, empirical therapy, or pre-emptive therapy of fungal infections in immunocompromised patients: which is better for whom?","volume":"15","author":"Leather","year":"2002","journal-title":"Curr Opin Infect Dis"},{"key":"10.1016\/j.jiac.2017.02.011_bib15","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1093\/jac\/dkq121","article-title":"Clinical effectiveness of posaconazole prophylaxis in patients with acute myelogenous leukaemia (AML): a 6 year experience of the Cologne AML cohort","volume":"65","author":"Vehreschild","year":"2010","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.jiac.2017.02.011_bib16","doi-asserted-by":"crossref","first-page":"459","DOI":"10.3324\/haematol.2011.051995","article-title":"Comparative clinical effectiveness of prophylactic voriconazole\/posaconazole to fluconazole\/itraconazole in patients with acute myeloid leukemia\/myelodysplastic syndrome undergoing cytotoxic chemotherapy over a 12-year period","volume":"97","author":"Ananda-Rajah","year":"2012","journal-title":"Haematologica"},{"issue":"Suppl.\u00a01","key":"10.1016\/j.jiac.2017.02.011_bib17","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1111\/j.1439-0507.2010.01979.x","article-title":"Posaconazole prophylaxis in patients with acute myelogenous leukaemia\u2013results from an observational study","volume":"54","author":"Egerer","year":"2011","journal-title":"Mycoses"},{"key":"10.1016\/j.jiac.2017.02.011_bib18","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1002\/cam4.225","article-title":"Clinical effectiveness of posaconazole versus fluconazole as antifungal prophylaxis in hematology-oncology patients: a retrospective cohort study","volume":"3","author":"Kung","year":"2014","journal-title":"Cancer Med"},{"key":"10.1016\/j.jiac.2017.02.011_bib19","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1007\/s00432-015-1962-x","article-title":"Efficacy of antifungal prophylaxis with oral suspension posaconazole during induction chemotherapy of acute myeloid leukemia","volume":"141","author":"Schrenk","year":"2015","journal-title":"J\u00a0Cancer Res Clin Oncol"},{"key":"10.1016\/j.jiac.2017.02.011_bib20","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1093\/cid\/cis773","article-title":"Evaluation of the practice of antifungal prophylaxis use in patients with newly diagnosed acute myeloid leukemia: results from the SEIFEM 2010-B registry","volume":"55","author":"Pagano","year":"2012","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jiac.2017.02.011_bib21","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1111\/myc.12357","article-title":"Posaconazole for primary antifungal prophylaxis in patients with acute myeloid leukaemia or myelodysplastic syndrome during remission induction chemotherapy: a single-centre retrospective study in Korea and clinical considerations","volume":"58","author":"Cho","year":"2015","journal-title":"Mycoses"},{"key":"10.1016\/j.jiac.2017.02.011_bib22","first-page":"315","article-title":"Prevention of invasive fungal infections in patients with acute myeloid leukaemia: results of a single centre retrospective observational study with the use of posaconazole versus conventional mould-active azoles","volume":"26","author":"Dellacasa","year":"2014","journal-title":"J\u00a0Chemother"},{"key":"10.1016\/j.jiac.2017.02.011_bib23","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1093\/cid\/civ542","article-title":"Antifungal prophylaxis with posaconazole is effective in preventing invasive fungal infections in acute myeloid leukemia patients during induction and salvage chemotherapy","volume":"61","author":"Wong","year":"2015","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jiac.2017.02.011_bib24","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1093\/jac\/dkv343","article-title":"Primary antifungal prophylaxis in adult patients with acute lymphoblastic leukaemia: a multicentre audit","volume":"71","author":"Doan","year":"2016","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.jiac.2017.02.011_bib25","first-page":"1128","article-title":"Itraconazole 800 mg for the prophylaxis of fungal infections in patients with acute leukemia and severe neutropenia","volume":"139","author":"Andrade","year":"2011","journal-title":"Rev Med Chil"},{"key":"10.1016\/j.jiac.2017.02.011_bib26","doi-asserted-by":"crossref","first-page":"e143","DOI":"10.1111\/j.1439-0507.2010.01860.x","article-title":"Posaconazole prophylaxis during induction therapy of patients with acute lymphoblastic leukaemia","volume":"54","author":"Illmer","year":"2011","journal-title":"Mycoses"},{"key":"10.1016\/j.jiac.2017.02.011_bib27","series-title":"Practice guidelines in oncology (version 1.2016): acute lymphoblastic leukemia","author":"National Comprehensive Cancer Network (NCCN)","year":"2016"},{"key":"10.1016\/j.jiac.2017.02.011_bib28","series-title":"Practice guidelines in oncology (version 2.2016): acute myoloid leukemia","author":"National Comprehensive Cancer Network (NCCN)","year":"2016"},{"key":"10.1016\/j.jiac.2017.02.011_bib29","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1093\/clinids\/21.2.361","article-title":"Invasive fungal disease in adults undergoing remission-induction therapy for acute myeloid leukemia: the pathogenetic role of the antileukemic regimen","volume":"21","author":"Bow","year":"1995","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jiac.2017.02.011_bib30","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1200\/JCO.2003.07.129","article-title":"Human granulocyte colony-stimulating factor in children with high-risk acute lymphoblastic leukemia: a Children's Cancer Group Study","volume":"21","author":"Heath","year":"2003","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jiac.2017.02.011_bib31","series-title":"Common toxicity criteria (version 2.0)","author":"European Organisation for Research and Treatment of Cancer","year":"1999"},{"key":"10.1016\/j.jiac.2017.02.011_bib32","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1128\/AAC.01985-15","article-title":"Network meta-analysis and pharmacoeconomic evaluation of fluconazole, itraconazole, posaconazole, and voriconazole in invasive fungal infection prophylaxis","volume":"60","author":"Zhao","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jiac.2017.02.011_bib33","first-page":"77","article-title":"Posaconazole vs fluconazole or itraconazole for prevention of invasive fungal diseases in patients with acute myeloid leukemia or myelodysplastic syndrome: a cost-effectiveness analysis in an Asian teaching hospital","volume":"19","author":"Chan","year":"2016","journal-title":"J\u00a0Med Econ"},{"key":"10.1016\/j.jiac.2017.02.011_bib34","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1007\/s40261-014-0199-9","article-title":"Economic evaluation of posaconazole versus fluconazole or itraconazole in the prevention of invasive fungal infection in high-risk neutropenic patients in Sweden","volume":"34","author":"Lundberg","year":"2014","journal-title":"Clin Drug Investig"},{"key":"10.1016\/j.jiac.2017.02.011_bib35","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1111\/j.1524-4733.2008.00486.x","article-title":"Cost-effectiveness of posaconazole versus fluconazole or itraconazole in the prevention of invasive fungal infections among neutropenic patients in the United States","volume":"12","author":"O'Sullivan","year":"2009","journal-title":"Value Health"},{"key":"10.1016\/j.jiac.2017.02.011_bib36","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1111\/j.1749-6632.2012.06829.x","article-title":"Risk stratification for invasive aspergillosis in immunocompromised patients","volume":"1272","author":"Herbrecht","year":"2012","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.jiac.2017.02.011_bib37","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1111\/ejh.12565","article-title":"Decreased invasive fungal disease but no impact on overall survival by posaconazole compared to fluconazole prophylaxis: a retrospective cohort study in patients receiving induction therapy for acute myeloid leukaemia\/myelodysplastic syndromes","volume":"96","author":"Dahlen","year":"2016","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.jiac.2017.02.011_bib38","doi-asserted-by":"crossref","first-page":"738","DOI":"10.5414\/CP201880","article-title":"Posaconazole vs. fluconazole as invasive fungal infection prophylaxis in China: a multicenter, randomized, open-label study","volume":"51","author":"Shen","year":"2013","journal-title":"Int J Clin Pharmacol Ther"},{"key":"10.1016\/j.jiac.2017.02.011_bib39","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1056\/NEJMoa061094","article-title":"Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia","volume":"356","author":"Cornely","year":"2007","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jiac.2017.02.011_bib40","doi-asserted-by":"crossref","first-page":"53","DOI":"10.4103\/0971-5851.177032","article-title":"Voriconazole is a safe and effective anti-fungal prophylactic agent during induction therapy of acute myeloid leukemia","volume":"37","author":"Shah","year":"2016","journal-title":"Indian J Med Paediatr Oncol"},{"key":"10.1016\/j.jiac.2017.02.011_bib41","doi-asserted-by":"crossref","first-page":"235","DOI":"10.4103\/2319-4170.143491","article-title":"Impact of fluconazole versus posaconazole prophylaxis on the incidence of fungal infections in patients receiving induction chemotherapy for acute myeloid leukemia","volume":"38","author":"Devanlay","year":"2015","journal-title":"Biomed J"},{"key":"10.1016\/j.jiac.2017.02.011_bib42","first-page":"19","article-title":"Efficacy and safety of intravenous voriconazole and intravenous itraconazole for antifungal prophylaxis in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome","volume":"19","author":"Mattiuzzi","year":"2011","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.jiac.2017.02.011_bib43","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1002\/cncr.11930","article-title":"Intravenous itraconazole for prophylaxis of systemic fungal infections in patients with acute myelogenous leukemia and high-risk myelodysplastic syndrome undergoing induction chemotherapy","volume":"100","author":"Mattiuzzi","year":"2004","journal-title":"Cancer"},{"key":"10.1016\/j.jiac.2017.02.011_bib44","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1128\/AAC.44.7.1887-1893.2000","article-title":"Itraconazole oral solution for primary prophylaxis of fungal infections in patients with hematological malignancy and profound neutropenia: a randomized, double-blind, double-placebo, multicenter trial comparing itraconazole and amphotericin B","volume":"44","author":"Harousseau","year":"2000","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jiac.2017.02.011_bib45","doi-asserted-by":"crossref","first-page":"996","DOI":"10.3324\/haematol.2009.012633","article-title":"Prophylaxis of invasive aspergillosis with voriconazole or caspofungin during building work in patients with acute leukemia","volume":"95","author":"Chabrol","year":"2010","journal-title":"Haematologica"},{"key":"10.1016\/j.jiac.2017.02.011_bib46","doi-asserted-by":"crossref","first-page":"e333","DOI":"10.1097\/MPH.0b013e3182331bc7","article-title":"Oral voriconazole versus intravenous low dose amphotericin B for primary antifungal prophylaxis in pediatric acute leukemia induction: a prospective, randomized, clinical study","volume":"33","author":"Mandhaniya","year":"2011","journal-title":"J\u00a0Pediatr Hematol Oncol"},{"key":"10.1016\/j.jiac.2017.02.011_bib47","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1002\/ajh.23388","article-title":"The incidence of invasive fungal infections in neutropenic patients with acute leukemia and myelodysplastic syndromes receiving primary antifungal prophylaxis with voriconazole","volume":"88","author":"Barreto","year":"2013","journal-title":"Am J Hematol"},{"key":"10.1016\/j.jiac.2017.02.011_bib48","first-page":"1231","article-title":"Vinca alkaloids","volume":"4","author":"Moudi","year":"2013","journal-title":"Int J Prev Med"},{"key":"10.1016\/j.jiac.2017.02.011_bib49","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1097\/01.mph.0000172751.06286.5b","article-title":"Itraconazole-related increased vincristine neurotoxicity: case report and review of literature","volume":"27","author":"Bermudez","year":"2005","journal-title":"J\u00a0Pediatr Hematol Oncol"},{"key":"10.1016\/j.jiac.2017.02.011_bib50","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1111\/j.1651-2227.2001.tb03257.x","article-title":"Potentiation of vincristine toxicity by itraconazole in children with lymphoid malignancies","volume":"90","author":"Kamaluddin","year":"2001","journal-title":"Acta Paediatr"},{"key":"10.1016\/j.jiac.2017.02.011_bib51","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1097\/MPH.0b013e31819b9d01","article-title":"Posaconazole-increased vincristine neurotoxicity in a child: a case report","volume":"31","author":"Eiden","year":"2009","journal-title":"J\u00a0Pediatr Hematol Oncol"},{"key":"10.1016\/j.jiac.2017.02.011_bib52","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1002\/pbc.22399","article-title":"Severe life threatening neurotoxicity in a child with acute lymphoblastic leukemia receiving posaconazole and vincristine","volume":"54","author":"Jain","year":"2010","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.jiac.2017.02.011_bib53","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1097\/MPH.0b013e318030d289","article-title":"Possible increase of the neurotoxicity of vincristine by the concurrent use of posaconazole in a young adult with leukemia","volume":"29","author":"Mantadakis","year":"2007","journal-title":"J\u00a0Pediatr Hematol Oncol"},{"key":"10.1016\/j.jiac.2017.02.011_bib54","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1111\/j.1439-0507.2011.02158.x","article-title":"Adverse interactions between antifungal azoles and vincristine: review and analysis of cases","volume":"55","author":"Moriyama","year":"2012","journal-title":"Mycoses"},{"key":"10.1016\/j.jiac.2017.02.011_bib55","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1007\/BF01697985","article-title":"Aggravation of vincristine-induced neurotoxicity by itraconazole in the treatment of adult ALL","volume":"71","author":"Bohme","year":"1995","journal-title":"Ann Hematol"},{"key":"10.1016\/j.jiac.2017.02.011_bib56","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1080\/088800101753328529","article-title":"Enhanced vincristine neurotoxicity from drug interactions: case report and review of literature","volume":"18","author":"Sathiapalan","year":"2001","journal-title":"Pediatr Hematol Oncol"},{"key":"10.1016\/j.jiac.2017.02.011_bib57","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1002\/ajh.20918","article-title":"Itraconazole-enhanced vindesine neurotoxicity in adult acute lymphoblastic leukaemia","volume":"82","author":"Chen","year":"2007","journal-title":"Am J Hematol"},{"key":"10.1016\/j.jiac.2017.02.011_bib58","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.12659\/MSM.893142","article-title":"Clinical analysis of adverse drug reactions between vincristine and triazoles in children with acute lymphoblastic leukemia","volume":"21","author":"Yang","year":"2015","journal-title":"Med Sci Monit"},{"key":"10.1016\/j.jiac.2017.02.011_bib59","doi-asserted-by":"crossref","first-page":"e75531","DOI":"10.1371\/journal.pone.0075531","article-title":"A\u00a0risk prediction score for invasive mold disease in patients with hematological malignancies","volume":"8","author":"Stanzani","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.jiac.2017.02.011_bib60","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1111\/imj.12595","article-title":"Consensus guidelines for antifungal prophylaxis in haematological malignancy and haemopoietic stem cell transplantation","volume":"2014","author":"Fleming","year":"2014","journal-title":"Intern Med J"},{"key":"10.1016\/j.jiac.2017.02.011_bib61","doi-asserted-by":"crossref","first-page":"3858","DOI":"10.1182\/blood-2014-04-516211","article-title":"How we treat invasive fungal diseases in patients with acute leukemia: the importance of an individualized approach","volume":"124","author":"Nucci","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.jiac.2017.02.011_bib62","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1086\/588298","article-title":"Characteristics and treatment outcome of cerebrospinal fluid shunt-associated infections in adults: a retrospective analysis over an 11-year period","volume":"47","author":"Conen","year":"2008","journal-title":"Clin Infect Dis"}],"container-title":["Journal of Infection and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1341321X17300442?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1341321X17300442?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T18:56:33Z","timestamp":1761159393000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1341321X17300442"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6]]},"references-count":62,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2017,6]]}},"alternative-id":["S1341321X17300442"],"URL":"https:\/\/doi.org\/10.1016\/j.jiac.2017.02.011","relation":{},"ISSN":["1341-321X"],"issn-type":[{"value":"1341-321X","type":"print"}],"subject":[],"published":{"date-parts":[[2017,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evaluation of the implementation rate of primary antifungal prophylaxis and the prognosis of invasive fungal disease in acute leukemia patients in China","name":"articletitle","label":"Article Title"},{"value":"Journal of Infection and Chemotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jiac.2017.02.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}